Table of Contents
Plaintiffs are now stepping forward to sue Dupixent manufacturers, claiming the drug caused Cutaneous T-Cell Lymphoma (CTCL), a type of skin cancer. Are you one among them? Read to know more about this issue on the Dupixent lawsuit.
While Dupixent has helped many, it may also carry serious risks for some patients. Emerging research suggests a possible link between Dupixent and cancer, raising serious safety questions.
This blog provides an overview of Dupixent, explains what CTCL is, and discusses the reasons behind the lawsuits, as well as what individuals should know if they have used this medication.
Dupixent (dupilumab) Injection
Dupixent is widely known by its generic name dupilumab and was approved by the U.S. Food and Drug Administration (FDA) in 2017. This drug is manufactured by Regeneron Pharmaceuticals and Sanofi, and it is used to treat some allergic conditions like asthma, eczema, and chronic sinusitis.
Sanofi reported nearly $5 billion in sales in the third quarter of 2025, a 26% increase from last year. Sanofi’s total global third-quarter revenue reached $14.55 billion, slightly higher than the company’s projected $14.46 billion. Sanofi expects Dupixent sales to reach $14.5 billion annually by 2031, when the drug’s patent expires.
The drug has become one of Sanofi’s top earners, bringing in over $15 billion in 2024 and continuing to drive record profits for the company. Most recently, the drug was approved in Canada to treat chronic obstructive pulmonary disease (COPD) in adults.
Despite its success, Sanofi is now facing growing safety concerns and potential Dupixent cancer lawsuits.
Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-Cell Lymphoma starts in T-cells, a type of white blood cell that normally helps the body fight infections. CTCL can cause a variety of symptoms; at first, it looks like eczema or psoriasis.
Common symptoms include:
- Rashes
- Red and itchy patches
- Scaly or dry skin areas
- Fatigue
The symptoms look like common skin conditions, so CTCL can be difficult to diagnose in the early stages.
There are different forms of CTCL, including:
- Mycosis fungoides – the most common form, a chronic condition that is usually slow-growing.
- Sézary syndrome – a more aggressive form, involving cancer cells in both the skin and the blood.
CTCL is a very rare condition, but it can become serious and life-threatening if not diagnosed early.
Link between Dupixent and CTCL
Dupixent (dupilumab) has been linked to a higher risk of CTCL. This association arises after several studies and case reports suggesting that the drug may accelerate the progression of this rare cancer.
In 2024, a study published in PubMed highlights the association between dupilumab and cutaneous T-cell lymphoma (CTCL). The study found patients who took dupilumab were about 4 times more likely to develop CTCL. Most of the cases appeared after a year of using dupilumab. Dupilumab use in eczema patients was linked to a higher chance of developing CTCL.
Dupixent may reduce eczema symptoms while CTCL is still developing, making the cancer harder to notice until it is more advanced.
The U.S. population-based cohort study (2018–2024) compared 14,936 asthma patients treated with dupilumab against 734,126 patients on ICS/LABA therapy.
The results indicated that dupilumab users had a higher risk of lymphoma, especially T-cell and NK-cell lymphomas. It also showed lower overall death rates compared to standard ICS/LABA therapy. This means the drug may help patients live longer with a higher cancer risk.
In March 2025, the FDA placed Dupixent on the FDA’s Adverse Event Reporting System “Potential Signals” list after reviewing over 300 reports of lymphoma tied to the drug. This step may lead to new black box warnings, safety communications, or labeling changes. In the 300 cases, 138 were cutaneous T-cell lymphoma.
The studies around Dupixent led to lawsuits against the makers of the drug, Sanofi and Regeneron.
Current Progress of the Lawsuits
Dupixent is still on the market, and for many people it provides important relief. The companies that make Dupixent did not provide enough warning to patients and doctors about the chance of developing CTCL and other cancers.
The Dupixent lawsuit is still in its early days. There is no Dupixent class action lawsuit right now. If any cases arise, we will inform you. If new evidence comes out or many more people come forward, the lawsuit may boom.
The future Dupixent lawsuits may state that the makers of Dupixent kept selling it and expanding its use without updating their safety warning labels, even as new danger signs appeared.
Wrongful Death Lawsuit Against Dupixent
On October 1, 2025, Chandra Richardson filed a wrongful death lawsuit against Regeneron Pharmaceuticals and Sanofi-Aventis, alleging that her mother, Cynthia Marie Hyde, died from peripheral T-cell lymphoma after being treated with Dupixent. The lawsuit claims the companies failed to warn of cancer risks.
The case was assigned to U.S. District Judge Eli J. Richardson, and on October 2, he issued a court order requiring both parties to be prepared to discuss key factual and legal issues, any obstacles to a potential settlement, and whether either side intends to file dispositive motions.
An initial case management conference is scheduled for December 8, 2025, and will be conducted via telephone under the supervision of Magistrate Judge Alistair Newbern. Both parties must attend and submit a case plan by December 5. This case could influence future lawsuits, as more law firms are now looking into cases where people developed T-cell lymphoma after using Dupixent.
Who May Be Eligible to File a Dupixent Lawsuit?
If you were using Dupixent for your allergic condition and later received cutaneous T-cell lymphoma or another T-cell lymphoma, you may be eligible to file a Dupixent lawsuit.
Lawyers reviewing these cases usually ask for medical records, treatment history, and proof of diagnosis.
If someone is worried about their experience with Dupixent, the most important step is to speak with a healthcare provider and consider reaching out to a lawyer for a free case evaluation. This way, anyone affected can get advice based on their situation, learn about legal rights, and find out what next steps make sense.
To sum up,
Taking medicine should make life better. When life-threatening side effects happen, especially ones as serious as cancer, the companies involved may be held legally responsible for not giving people the information they need to make safe choices.
As more evidence about the drug comes out, the FDA may push for stronger safety labels or new studies. For patients and doctors, staying alert to the risks is crucial. With accurate information and early diagnosis, the outcome can be life-saving.
